By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Celldex Therapeutics, Inc. 

222 Cameron Drive
Suite 400
Phillipsburg  New Jersey  08865  U.S.A.
Phone: 908-454-7120 Fax: 908-454-1911


SEARCH JOBS


Industry
Biotechnology






Company News
Independent Data Safety And Monitoring Board Recommends Continuation Of Celldex (CLDX)'s Phase III Study Of RINTEGA (Rindopepimut) In Newly Diagnosed Glioblastoma 6/29/2015 7:29:58 AM
ASCO15: Celldex (CLDX) Release: Randomized Phase 2 React Study Of RINTEGA In Recurrent Bevacizumab-Naive Glioblastoma Demonstrates Statistically Significant Overall Survival And Emergence Of Long-Term Survival Benefit; Primary Endpoint Of PFS6 Met 6/1/2015 5:54:56 AM
ASCO15: Hope Rises As Celldex (CLDX)'s Brain Cancer Vaccine Helps Patients Live Longer 6/1/2015 5:53:51 AM
Celldex (CLDX)'s Brain Cancer Drug Rintega Will Take Center Stage at ASCO 5/29/2015 10:12:04 AM
Celldex (CLDX) To Present At The Jefferies and Co. 2015 Global Healthcare Conference 5/28/2015 7:07:27 AM
Celldex (CLDX) To Present Data From The React Study At 2015 ASCO Annual Meeting 5/14/2015 12:58:04 PM
Celldex (CLDX) Reports First Quarter 2015 Results 4/29/2015 11:14:01 AM
Celldex (CLDX)'s Varlilumab Demonstrates Synergistic Anti-Tumor Activity With PD-1 Signaling Blockade In Preclinical Studies 4/20/2015 8:42:33 AM
Celldex (CLDX)' Phase 2 EMERGE Study Of Glembatumumab Vedotin In Metastatic Breast Cancer Published In Journal Of Clinical Oncology 4/7/2015 6:53:22 AM
Celldex (CLDX) Announces Initiation Of Phase 1/2 Study Of Varlilumab In Combination With Ipilimumab And CDX-1401 In Metastatic Melanoma 4/6/2015 7:05:39 AM
12345678910...
//-->